Rhumbline Advisers Prelude Therapeutics Inc Transaction History

Rhumbline Advisers

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 08, 2025	SELL	$0.64 - $1.39 $96,851 - $210,350	-151,331 Reduced 90.71%	15,499 $12,000
Q4 2024 May 29, 2025	BUY	$0.8 - $2.04 $121,064 - $308,715	151,331 Added 976.39%	166,830 $211,000
Q4 2024 Jan 30, 2025	BUY	$0.8 - $2.04 $123,860 - $315,845	154,826 Added 1289.79%	166,830 $211,000
Q3 2024 Nov 12, 2024	SELL	$2.07 - $6.37 $19,791 - $60,903	-9,561 Reduced 44.34%	12,004 $24,000
Q2 2024 Aug 01, 2024	BUY	$3.32 - $5.63 $1,324 - $2,246	399 Added 1.89%	21,565 $82,000
Q1 2024 May 09, 2024	BUY	$2.68 - $4.84 $2,044 - $3,692	763 Added 3.74%	21,166 $100,000
Q4 2023 Feb 08, 2024	SELL	$1.69 - $4.37 $22,666 - $58,610	-13,412 Reduced 39.66%	20,403 $87,000
Q3 2023 Nov 09, 2023	BUY	$2.74 - $4.79 $10,949 - $19,140	3,996 Added 13.4%	33,815 $104,000
Q2 2023 Aug 08, 2023	BUY	$4.45 - $8.12 $132,694 - $242,130	29,819 New	29,819 $134,000
Q2 2022 Aug 11, 2022	SELL	$4.0 - $7.55 $40,200 - $75,877	-10,050 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$6.9 - $13.22 $69,345 - $132,861	10,050 New	10,050 $69,000
Q4 2021 Feb 10, 2022	SELL	$11.89 - $31.74 $110,279 - $294,388	-9,275 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$25.78 - $38.65 $12,890 - $19,325	500 Added 5.7%	9,275 $290,000
Q2 2021 Aug 05, 2021	SELL	$28.63 - $44.3 $25,366 - $39,249	-886 Reduced 9.17%	8,775 $251,000
Q1 2021 May 06, 2021	BUY	$39.27 - $91.68 $4,516 - $10,543	115 Added 1.2%	9,661 $419,000
Q4 2020 Feb 10, 2021	BUY	$28.81 - $88.94 $275,020 - $849,021	9,546 New	9,546 $683,000

27.9M

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $30.6M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.